Amgen and Merck will
collaborate to evaluate the safety
and efficacy of a drug combination
to treat patients with mid to late
stage melanoma.
The companies said they had
entered an agreement through a
subsidiary to investigate talimogene
laherparepvec, an investigational
oncolytic immunotherapy
combined with MK-3475,
an investigational anti-PD-1
immunotherapy, in a phase 1b/2
study.
The open-label clinical trial would
be conducted in two parts in
autumn.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Feb 14
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.